PL3470397T3 - Postacie krystaliczne inhibitora hydroksylazy prolilowej - Google Patents

Postacie krystaliczne inhibitora hydroksylazy prolilowej

Info

Publication number
PL3470397T3
PL3470397T3 PL18189607T PL18189607T PL3470397T3 PL 3470397 T3 PL3470397 T3 PL 3470397T3 PL 18189607 T PL18189607 T PL 18189607T PL 18189607 T PL18189607 T PL 18189607T PL 3470397 T3 PL3470397 T3 PL 3470397T3
Authority
PL
Poland
Prior art keywords
crystalline forms
prolyl hydroxylase
hydroxylase inhibitor
inhibitor
prolyl
Prior art date
Application number
PL18189607T
Other languages
English (en)
Polish (pl)
Inventor
Claudia WITSCHI
Jung Min Park
Michael D. Thompson
Michael John Martinelli
David A. Yeowell
Michael P. Arend
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3470397(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of PL3470397T3 publication Critical patent/PL3470397T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
PL18189607T 2012-07-16 2013-07-15 Postacie krystaliczne inhibitora hydroksylazy prolilowej PL3470397T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US201361768297P 2013-02-22 2013-02-22
US201361832566P 2013-06-07 2013-06-07
EP13740185.7A EP2872488B1 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor
PCT/US2013/050539 WO2014014835A2 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor
EP18189607.7A EP3470397B1 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
PL3470397T3 true PL3470397T3 (pl) 2022-06-20

Family

ID=48857025

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13740185T PL2872488T3 (pl) 2012-07-16 2013-07-15 Postacie krystaliczne inhibitora hydroksylazy prolilowej
PL18189607T PL3470397T3 (pl) 2012-07-16 2013-07-15 Postacie krystaliczne inhibitora hydroksylazy prolilowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13740185T PL2872488T3 (pl) 2012-07-16 2013-07-15 Postacie krystaliczne inhibitora hydroksylazy prolilowej

Country Status (29)

Country Link
US (5) US9115085B2 (show.php)
EP (3) EP2872488B1 (show.php)
JP (2) JP6491093B2 (show.php)
KR (4) KR102318720B1 (show.php)
CN (9) CN115093370A (show.php)
AU (1) AU2013290438C1 (show.php)
BR (1) BR112015001101A2 (show.php)
CA (1) CA2879242C (show.php)
CY (2) CY1120805T1 (show.php)
DK (2) DK2872488T3 (show.php)
ES (2) ES2905898T3 (show.php)
FR (1) FR22C1030I2 (show.php)
HK (1) HK1243409A1 (show.php)
HR (2) HRP20181751T1 (show.php)
HU (2) HUE041458T2 (show.php)
IL (1) IL236626B (show.php)
IN (1) IN2015KN00262A (show.php)
LT (3) LT2872488T (show.php)
MX (1) MX355428B (show.php)
MY (1) MY182428A (show.php)
NO (1) NO2022024I1 (show.php)
NZ (1) NZ704662A (show.php)
PL (2) PL2872488T3 (show.php)
PT (2) PT3470397T (show.php)
RS (2) RS57795B1 (show.php)
SG (3) SG10202111314YA (show.php)
SI (2) SI2872488T1 (show.php)
SM (2) SMT202200095T1 (show.php)
WO (1) WO2014014835A2 (show.php)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543448A (en) 2003-06-06 2009-02-28 Fibrogen Inc Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN115093370A (zh) 2012-07-16 2022-09-23 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
MX2015016536A (es) 2013-06-06 2016-08-11 Fibrogen Inc Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106916105A (zh) * 2015-12-28 2017-07-04 徐州万邦金桥制药有限公司 一种纯化可博美的方法
WO2017143131A1 (en) * 2016-02-19 2017-08-24 Cornell University Hif-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
CN107382986B (zh) * 2017-08-02 2022-09-20 江苏艾立康医药科技有限公司 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
WO2019030711A1 (en) * 2017-08-11 2019-02-14 Dr. Reddy’S Laboratories Limited POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CA3074529C (en) 2017-09-04 2022-07-05 Sandoz Ag Co-crystal of roxadustat with l-proline and uses thereof
CN112166105B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途
CN111320583A (zh) * 2018-12-14 2020-06-23 广东东阳光药业有限公司 诺德司他新晶型及其制备方法
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2020217190A1 (en) * 2019-04-26 2020-10-29 Dr. Reddy’S Laboratories Limited Process for the purification of roxadustat
CN112679428A (zh) * 2019-10-17 2021-04-20 罗欣药业(上海)有限公司 罗沙司他新晶型及其制备方法
CN114344301B (zh) * 2019-10-22 2023-06-23 苏州科睿思制药有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
CN110721185B (zh) * 2019-11-13 2022-04-12 南京市儿童医院 罗沙司他用于心肌保护的用途
CN112961107B (zh) * 2019-12-13 2024-06-25 罗欣药业(上海)有限公司 罗沙司他的晶型及其制备方法
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
CN111205224B (zh) * 2020-04-22 2020-08-25 南京佰麦生物技术有限公司 一种罗沙司他水合物的晶型及其制备方法和应用
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN114057643B (zh) * 2020-08-04 2023-02-28 成都苑东生物制药股份有限公司 一种罗沙司他共晶及其制备方法
CN112500344B (zh) * 2020-11-18 2022-07-01 江苏豪森药业集团有限公司 罗沙司他晶型及其制备方法
CN112194624A (zh) * 2020-11-18 2021-01-08 江苏豪森药业集团有限公司 一种异喹啉类化合物的晶型及其制备方法
CN115724796A (zh) * 2021-08-26 2023-03-03 成都苑东生物制药股份有限公司 一种罗沙司他新晶型及其制备方法
CN113956200A (zh) * 2021-12-16 2022-01-21 南京威凯尔生物医药科技有限公司 一种粒径控制的罗沙司他原料药的结晶工艺
CN116410134A (zh) * 2021-12-31 2023-07-11 北京济美堂医药研究有限公司 一种罗沙司他水合物晶体及其制备方法和应用
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
AU5362998A (en) 1996-11-27 1998-06-22 Du Pont Pharmaceuticals Company Novel integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1315220B1 (it) * 1999-12-13 2003-02-03 Ipm Ind Plastica Monregalese Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
EP1379630B1 (en) 2001-03-21 2012-09-26 Isis Innovation Limited Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
WO2002100832A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US20030176317A1 (en) 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
CN100339078C (zh) 2002-12-16 2007-09-26 橘生药品工业株式会社 固体口服剂型药物
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
NZ543448A (en) 2003-06-06 2009-02-28 Fibrogen Inc Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
AU2004259675A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine CGRP receptor antagonists
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
EP1726306B1 (en) 2004-03-16 2013-10-30 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
CA2567619A1 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
GB2421013B (en) 2004-12-10 2007-07-11 Amcor Flexibles Europe As Packaging with an openable top wall
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
AU2007211077B2 (en) 2006-01-27 2012-09-20 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
US20100172984A1 (en) 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
EP2433620A1 (en) 2007-10-12 2012-03-28 AstraZeneca AB Zibotentan Composition
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
JP5479949B2 (ja) 2009-04-08 2014-04-23 株式会社東芝 測定装置、測定方法、及び二酸化炭素回収システム
JP2010248106A (ja) 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US8339523B2 (en) 2010-05-18 2012-12-25 Kabushiki Kaisha Toshiba Television apparatus and electronic apparatus
CN101880914B (zh) 2010-05-25 2012-09-12 中国科学院微电子研究所 利用等离子体浸没离子注入制备黑硅的方法
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
JP6099644B2 (ja) * 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
NZ700760A (en) 2012-03-09 2016-08-26 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN115093370A (zh) * 2012-07-16 2022-09-23 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
MX360048B (es) 2013-01-24 2018-10-19 Fibrogen Inc Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2015016536A (es) 2013-06-06 2016-08-11 Fibrogen Inc Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif.

Also Published As

Publication number Publication date
CN103539735A (zh) 2014-01-29
WO2014014835A8 (en) 2014-11-20
US20150322015A1 (en) 2015-11-12
AU2013290438C1 (en) 2019-01-03
KR102318720B1 (ko) 2021-10-28
JP6491093B2 (ja) 2019-03-27
KR20150058154A (ko) 2015-05-28
MX355428B (es) 2018-04-18
DK3470397T3 (da) 2022-03-14
KR20210130849A (ko) 2021-11-01
KR102149380B1 (ko) 2020-08-28
HRP20181751T1 (hr) 2018-12-28
SMT201800565T1 (it) 2018-11-09
CN114409596A (zh) 2022-04-29
AU2013290438A1 (en) 2015-02-19
US20140303202A9 (en) 2014-10-09
SI3470397T1 (sl) 2022-07-29
LT2872488T (lt) 2018-10-25
LTC3470397I2 (show.php) 2024-11-11
DK2872488T3 (en) 2018-10-29
WO2014014835A3 (en) 2014-08-21
HRP20220182T1 (hr) 2022-04-29
SMT202200095T1 (it) 2022-03-21
SG11201500236SA (en) 2015-02-27
CY1125155T1 (el) 2023-01-05
IL236626A0 (en) 2015-02-26
FR22C1030I2 (fr) 2024-08-02
CN107540607A (zh) 2018-01-05
US10118897B2 (en) 2018-11-06
PT3470397T (pt) 2022-02-18
HUE057925T2 (hu) 2022-06-28
LT3470397T (lt) 2022-02-25
HK1243409A1 (zh) 2018-07-13
NO2022024I1 (no) 2022-06-15
MX2015000504A (es) 2015-07-17
NZ704662A (en) 2017-07-28
CN107382859B (zh) 2018-09-14
US20140024676A1 (en) 2014-01-23
CN107501177B (zh) 2018-12-07
MY182428A (en) 2021-01-25
LTPA2022510I1 (show.php) 2022-07-25
FR22C1030I1 (fr) 2022-09-09
CN115093370A (zh) 2022-09-23
EP2872488B1 (en) 2018-08-22
EP4029854A1 (en) 2022-07-20
EP3470397B1 (en) 2021-12-29
JP2015522616A (ja) 2015-08-06
CN103539735B (zh) 2017-08-04
RS63122B1 (sr) 2022-05-31
IN2015KN00262A (show.php) 2015-06-12
WO2014014835A2 (en) 2014-01-23
EP3470397A1 (en) 2019-04-17
JP2018009034A (ja) 2018-01-18
CN107382859A (zh) 2017-11-24
US9617218B2 (en) 2017-04-11
SG10202111314YA (en) 2021-12-30
AU2013290438B2 (en) 2017-09-14
PL2872488T3 (pl) 2019-01-31
US9115085B2 (en) 2015-08-25
US20200115344A1 (en) 2020-04-16
HUE041458T2 (hu) 2019-05-28
IL236626B (en) 2020-03-31
AU2013290438B9 (en) 2018-07-19
CA2879242A1 (en) 2014-01-23
SI2872488T1 (sl) 2018-11-30
CA2879242C (en) 2023-05-09
CN107382860A (zh) 2017-11-24
BR112015001101A2 (pt) 2017-06-27
ES2905898T3 (es) 2022-04-12
EP2872488A2 (en) 2015-05-20
SG10201700873UA (en) 2017-04-27
KR20220164068A (ko) 2022-12-12
KR20200102556A (ko) 2020-08-31
RS57795B1 (sr) 2018-12-31
ES2689430T3 (es) 2018-11-14
CN104684897A (zh) 2015-06-03
US20170190667A1 (en) 2017-07-06
US20190276408A1 (en) 2019-09-12
CY1120805T1 (el) 2019-12-11
CN109369524A (zh) 2019-02-22
PT2872488T (pt) 2018-11-22
CN107501177A (zh) 2017-12-22

Similar Documents

Publication Publication Date Title
HUS2200030I1 (hu) Prolil hidroxiláz inhibitor kristályos alakjai
PL3470397T3 (pl) Postacie krystaliczne inhibitora hydroksylazy prolilowej
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
HUE036259T2 (hu) Inhibitor vegyületek
IL230580A0 (en) Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
HRP20181786T1 (hr) Inhibitori aktivacije t-stanica
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
CO7071137A2 (es) Compuetos inhibidores de beta-lactamasas
EP2734529A4 (en) BTK INHIBITORS
DK2710007T3 (da) Kinasehæmmere
HRP20181533T1 (hr) Antikancerogeni piridopirazini putem inhibitora fgfr kinaze
HUE047888T2 (hu) Glükozilceramid-szintáz-inhibitor
BR112014003214A2 (pt) polimorfos inibidores de cinase
LT2841428T (lt) Dnr-pk inhibitoriai
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
CO6970602A2 (es) Inhibidores de quinasa
DK3590934T3 (da) Pyrazolylquinoxalinkinasehæmmere
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
PL2906551T3 (pl) Postacie krystaliczne inhibitora czynnika xia
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
IL231950B (en) Aryl-quinoline derivatives
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
EP2753176A4 (en) HIV INHIBITORS
EP2682221A4 (en) FLUX
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion